PX-866: Phase II expanded

Oncothyreon said it expanded an open-label, Canadian Phase II trial evaluating once-daily 8 mg oral PX-866 in about 40 patients who received no prior therapy to include a second part in an additional 25 patients who have progressed while receiving Zytiga abiraterone and prednisone. The second part will evaluate PX-866 plus Zytiga and prednisone and will begin once the first part, which has enrolled 36 of the 40 planned patients, completes enrollment. The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) is conducting the trial. ...